Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317418 | 0.79 | MCL1 (0.51) | GRM5ADORA1ADORA2AADORA3 | |
| Methane SCHEMBL21731293 | 0.71 | GRM5 (0.43) | GRM5 | |
| SCHEMBL28331914 | 0.71 | PDGFRB (0.43) | GRM5ADORA2AKMT2AMEN1MAPT | |
| SCHEMBL1829827 | 0.69 | HRH1 (0.65) | TSHR | |
| SCHEMBL17379469 | 0.69 | GRM5 (0.62) | GRM5 | |
| SCHEMBL14927901 | 0.69 | ADORA2A (0.55) | ADORA1ADORA2AKMT2AMEN1MAPT | |
| SCHEMBL10231904 | 0.69 | NAAA (0.57) | KMT2AMEN1TSHREGFR | |
| SCHEMBL12247661 | 0.68 | GRM5 (0.45) | GRM5 | |
| SCHEMBL3848271 | 0.68 | KMT2A (0.53) | ADORA1ADORA2AKMT2AMEN1MAPT | |
| SCHEMBL316979 | 0.68 | MEN1 (0.58) | ADORA1ADORA2AKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-2081903-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008044217-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | GRM5 558/4885ADORA1 29/4885ADORA2A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.